mRNA vaccine developer Moderna (MRNA) is sinking 9% after GoldmanSachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its ...
Some results have been hidden because they may be inaccessible to you